Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050

Sharma, Rajesh

doi:10.1007/s10147-021-02108-2

Cited by 110 publications

(53 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Nicolet iS10 spectrometer from Thermo Scientific was used to record IR spectra (KBr). The 1 H NMR and 13 C NMR spectra were recorded by JEOL's (500 MHz) and Bruker NMR spectrometers (400 MHz) in DMSO-d 6 and CDCl 3 . Mass spectra was measured through Thermo Scientific GC/ MS model ISQ.…”

Section: Methodsmentioning

confidence: 99%

“…The protons of an aromatic system in the range from δ 6.95 to 7.42 ppm were observed as doublet and multiplet signals. In addition, 13 C NMR spectrum showed 20 carbon signals for thirty-two carbon atoms, the signal distinct at 20.89 ppm for methyl group. Furthermore, the mass spectrum displayed a molecular ion peak at m/z = 493 (15.10%) corresponding to the molecular weight of its chemical formula (C 32 H 23 N 5 O).…”

Section: Chemistrymentioning

confidence: 99%

“…above 300 °C. IR (ῡ, cm −1 ): 3301, 3210 (NH 2 ), 2224 (C≡N), 1686 (C = O); 1 H NMR (DMSO-d 6 ): δ (ppm): 6.95 (d, J = 9.00 Hz, 2H, Ar-H), 7.15-7.17 (m, 6H, Ar-H), 7.39 (t, J = 9.50 H, 6H, Ar-H), 7.67 (d, J = 8.00 Hz, 2H, Ar-H), 8.38 (d, J = 9.00 Hz, 2H, Ar-H); 13…”

Section: -Amino-4-(4-(diphenylamino)phenyl)-1-(4-nitrophenyl)-2oxo-12...mentioning

confidence: 99%

“…Over and above, new cancer cases are expected to increase to 29.5 million per year and cancer cases related deaths are projected to increase to 16.4 million in 2040 [ 12 ]. Meanwhile, the global encumbrance of lung cancer will be projected to reach 3.8 million new cases and 3.2 million deaths each year in 2050 [ 13 ]. Presently, there are more than 100 types of cancer, and each cancer type needs a diagnosis, so it has drawn the attention of scientists and chemists to develop new anticancer drugs with low toxicity, improved potency, and multiple mechanisms of action [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents

et al. 2022

View full text Add to dashboard Cite

A new series of pyridine, thiazole, and pyrazole analogues were synthesized. The pyridone analogues 4a-e were synthesized by treating N-aryl-2-cyano-3-(4-(diphenylamino)phenyl)acrylamides 3a-e with malononitrile. Many 4-arylidene-thiazolidin-5-one analogues 6a-d were obtained by Knoevenagel reactions of 4-(diphenylamino)benzaldehyde (1) with their corresponding thiazolidin-5-one derivatives 5a-d. The structural elucidation of the products was proven by the collections of spectroscopic methods such as IR, 1H NMR, 13C NMR, and MS data. Their anti-cancer activity was examined against two cell lines, MDA-MB-231 (mammary carcinomas) and A-549 (lung cancer). Compared with cisplatin as a reference standard drug, 6-amino-4-(4-(diphenylamino)phenyl)-2-oxo-1-(p-tolyl)-1,2-dihydropyridine-3,5-dicarbonitrile (4b) and 6-amino-4-(4-(diphenylamino)phenyl)-1-(4-nitrophenyl)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitrile (4e) exhibited better efficiency against the A-549 cell line, with IC50 = 0.00803 and 0.0095 μM, respectively. Also, these compounds 4b and 4e showed the most potency among the examined compounds against MDA-MB-231 with IC50 = 0.0103 and 0.0147 μM, respectively. The newly synthesized compounds were docked inside the active sites of the selected proteins and were found to demonstrate proper binding. 2-Cyano-2-(4,4-(diphenylamino)benzylidene)-5-oxo-3-phenylthiazolidin-2-ylidene)-N-(p-tolyl)acetamide (6c) offered the highest binding affinity (− 8.1868 kcal/mol) when docked into (PDB ID:2ITO), in addition to 2-cyano-N-(4-(diethylamino)phenyl)-2-(4-(4-(diphenylamino)benzylidene)-5-oxo-3-phenylthiazolidin-2-ylidene)acetamide (6a) gave the highest energy score (− 9.3507 kcal/mol) with (PDB ID:2A4L).

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Chemistrymentioning

confidence: 99%

Section: -Amino-4-(4-(diphenylamino)phenyl)-1-(4-nitrophenyl)-2oxo-12...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Cancer is the second leading cause of death in noncommunicable chronic diseases, and lung cancer still makes the maximum contribution to cancer-related mortality worldwide (1)(2)(3). With rapid economic development and population aging, newly diagnosed lung cancer cases in China will grow with a rate of 70% at least in the coming 20 years (2,4).…”

Section: Introductionmentioning

confidence: 99%

Establishment of a Nomogram-Based Prognostic Model (LASSO-COX Regression) for Predicting Progression-Free Survival of Primary Non-Small Cell Lung Cancer Patients Treated with Adjuvant Chinese Herbal Medicines Therapy: A Retrospective Study of Case Series

et al. 2022

View full text Add to dashboard Cite

Nowadays, Jin-Fu-Kang oral liquid (JFK), one of Chinese herbal medicines (CHMs) preparations, has been widely used as an adjuvant therapy for primary non-small cell lung cancer (PNSCLC) patients with the syndrome of deficiency of both Qi and Yin (Qi–Yin deficiency pattern) based on Traditional Chinese Medicine (TCM) theory. However, we found insufficient evidence of how long-term CHM treatment influence PNSCLC patients’ progression-free survival (PFS). Thus, using electronic medical records, we established a nomograph-based prognostic model for predicting PNSCLC patients’ PFS involved with JFK supplementary formulas (JFK-SFs) over 6 months, in order to preliminarily investigate potential predictors highly related to adjuvant CHMs therapies in theoretical epidemiology. In our retrospective study, a series of 197 PNSCLC cases from Long Hua Hospital were enrolled by non-probability sampling and divided into 2 datasets at the ratio of 5:4 by Kennard–Stone algorithm, as a result of 109 in training dataset and 88 in validation dataset. Besides, TNM stage, operation history, sIL-2R, and CA724 were considered as 4 highly correlated predictors for modeling based on LASSO-Cox regression. Additionally, we respectively used training dataset and validation dataset for establishment including internal validation and external validation, and the prediction performance of model was measured by concordance index (C-index), integrated discrimination improvement, and net reclassification indices (NRI). Moreover, we found that the model containing clinical characteristics and bio-features presented the best performance by pairwise comparison. Next, the result of sensitivity analysis proved its stability. Then, for preliminarily examination of its discriminative power, all eligible cases were divided into high-risk or low-risk progression by the cut-off value of 57, in the light of predicted nomogram scores. Ultimately, a completed TRIPOD checklist was used for self-assessment of normativity and integrity in modeling. In conclusion, our model might offer crude probability of uncertainly individualized PFS with long-term CHMs therapy in the real-world setting, which could discern the individuals implicated with worse prognosis from the better ones. Nevertheless, our findings were prone to unmeasured bias caused by confounding factors, owing to retrospective cases series.

show abstract

Global Disparities of Cancer and Its Projected Burden in 2050

Bizuayehu,

Ahmed,

Kibret

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceCancer prevention and care efforts have been challenged by the COVID-19 pandemic and armed conflicts, resulting in a decline in the global Human Development Index (HDI), particularly in low- and middle-income countries. These challenges and subsequent shifts in health care priorities underscore the need to continuously monitor cancer outcome disparities and statistics globally to ensure delivery of equitable and optimal cancer prevention and care in uncertain times.ObjectiveTo measure the global burden of 36 cancers in 2022 by sex, age, and geographic location and to project future trends by 2050.Design, Setting, and ParticipantsThis cross-sectional study used population-based data from 2022 in 185 countries and territories were obtained from the Global Cancer Observatory database. Data extraction and analysis were carried out in April 2024.Main Outcomes and MeasuresCounts, rates, prevalence, mortality to incidence ratios (MIRs), and demography-based projections were used to characterize current and future cancer burden.ResultsThis population-based study included 36 cancer types from 185 countries and territories. By 2050, 35.3 million cancer cases worldwide are expected, a 76.6% increase from the 2022 estimate of 20 million. Similarly, 18.5 million cancer deaths are projected by 2050, an 89.7% increase from the 2022 estimate of 9.7 million. Cancer cases and deaths are projected to nearly triple in low-HDI countries by 2050, compared to a moderate increase in very high–HDI countries (142.1% vs 41.7% for cancer cases and 146.1% vs 56.8% for cancer deaths). Males had a higher incidence and greater number of deaths in 2022 than females, with this disparity projected to widen by up to 16.0% in 2050. In 2022, the MIR for all cancers was 46.6%, with higher MIRs observed for pancreatic cancer (89.4%), among males (51.7%), among those aged 75 years or older (64.3%), in low-HDI countries (69.9%), and in the African region (67.2%).Conclusions and RelevanceIn this cross-sectional study based on data from 2022, cancer disparities were evident across HDI, geographic regions, age, and sex, with further widening projected by 2050. These findings suggest that strengthening access to and quality of health care, including universal health insurance coverage, is key to providing evidence-based cancer prevention, diagnostics, and care.

show abstract

Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050

Cited by 110 publications

References 35 publications

Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents

Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents

Establishment of a Nomogram-Based Prognostic Model (LASSO-COX Regression) for Predicting Progression-Free Survival of Primary Non-Small Cell Lung Cancer Patients Treated with Adjuvant Chinese Herbal Medicines Therapy: A Retrospective Study of Case Series

Global Disparities of Cancer and Its Projected Burden in 2050

Contact Info

Product

Resources

About